PDS Biotechnology Corp Files 8-K
Ticker: PDSB · Form: 8-K · Filed: Dec 9, 2025 · CIK: 1472091
| Field | Detail |
|---|---|
| Company | Pds Biotechnology Corp (PDSB) |
| Form Type | 8-K |
| Filed Date | Dec 9, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.00033 |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, sec-filing
TL;DR
PDS Biotech filed an 8-K on 12/9/25. Standard disclosure.
AI Summary
On December 9, 2025, PDS Biotechnology Corporation filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits. It was filed as of December 9, 2025, with the SEC. The company is incorporated in Delaware and its principal executive offices are located in Princeton, NJ.
Why It Matters
This 8-K filing indicates a routine update or disclosure from PDS Biotechnology Corp to the SEC, potentially containing important information for investors regarding company events or financial status.
Risk Assessment
Risk Level: low — This filing appears to be a standard disclosure and does not immediately indicate significant new risks or material adverse events.
Key Players & Entities
- PDS Biotechnology Corporation (company) — Registrant
- December 9, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- Princeton, NJ (location) — Principal Executive Offices
- Edge Therapeutics, Inc. (company) — Former Company Name
FAQ
What is the primary purpose of this 8-K filing for PDS Biotechnology Corporation?
The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of December 9, 2025.
When was this 8-K report filed by PDS Biotechnology Corporation?
The 8-K report was filed as of December 9, 2025.
In which state is PDS Biotechnology Corporation incorporated?
PDS Biotechnology Corporation is incorporated in Delaware.
What is the address of PDS Biotechnology Corporation's principal executive offices?
The principal executive offices of PDS Biotechnology Corporation are located at 303A College Road East, Princeton, NJ 08540.
Was PDS Biotechnology Corporation previously known by another name?
Yes, PDS Biotechnology Corporation was formerly known as Edge Therapeutics, Inc., with a date of name change on September 11, 2009.
Filing Stats: 512 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2025-12-09 08:05:38
Key Financial Figures
- $0.00033 — ch registered Common Stock, par value $0.00033 per share PDSB The Nasdaq Capital M
Filing Documents
- ef20060919_8k.htm (8-K) — 27KB
- ef20060919_ex99-1.htm (EX-99.1) — 15KB
- image00001.jpg (GRAPHIC) — 3KB
- 0001140361-25-044940.txt ( ) — 176KB
- pdsb-20251209.xsd (EX-101.SCH) — 4KB
- pdsb-20251209_lab.xml (EX-101.LAB) — 21KB
- pdsb-20251209_pre.xml (EX-101.PRE) — 16KB
- ef20060919_8k_htm.xml (XML) — 4KB
01
Item 8.01 Other Events. On December 9, 2025, PDS Biotechnology Corporation issued a press release announcing that the Japan Patent Office has issued Patent No. 7783866 for PDS0101 granting broad composition of matter and methods of use claims. The new patent expands previously granted patents in Japan, and adds to the Company's robust intellectual property estate, which includes previously granted patents in the United States, China, Australia, and Hong Kong. The Company has additional patent applications pending in several other countries. Together with anticipated biologics exclusivity in the United States, the Company has patent and market protections for PDS0101 into the 2040s. A copy of the press release is filed herewith as Exhibit 99.1 and incorporated by reference herein.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release Dated December 9, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document). Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PDS BIOTECHNOLOGY CORPORATION Date: December 9, 2025 By: /s/ Frank Bedu-Addo, Ph.D. Name: Frank Bedu-Addo, Ph.D. Title: President and Chief Executive Officer